0

Inovio’s DNA Vaccine Gives 100% For MERS virus in Non-Human Primates

(BiotechPickList) – Inovio Pharmaceuticals (NASDAQ:INO) has done it again and that is that it showed a 100% protection in non-human primates with the MERS virus. We say Inovio has done it again because Inovio’s DNA vaccine technology has been shown… Continue Reading

0

Eleven Biotherapeutics Soars 80% After Initiating Phase 3 Trial For Allergic Conjunctivitis

(BiotechPickList) – Shares of Eleven Biotherapeutics (NASDAQ:EBIO) soared up 80% today after initiating a phase 3 trial for patients with Allergic Conjunctivitis. Eleven Bio is a biotechnology company focused on the development of eye therapeutics. Today’s press release from the… Continue Reading

0

Rxi Pharmaceuticals Should Be On Your Radar Before Major Catalysts

(BiotechPickList) – Rxi Pharmaceuticals (NASDAQ:RXII) is set to release financial results for the 2nd quarter of 2015.  Typically the company comes in line or beats in revenue but as of now Rxi has no revenue coming from products in its… Continue Reading

0

Novavax Announces Positive Phase 2 Results For Its Seasonal Influenza Vaccine

(BiotechPickList) – On July 30, 2015 Novavax (NASDAQ:NVAX) announced positive phase 2 results for its seasonal influenza vaccine that uses the company’s VLP platform. The VLP platform stands for “Virus Like Particles” and they are used to generate multiple antigen… Continue Reading

0

Exelixis Announces Positive Phase 3 Results In Patients With Kidney Cancer

Today Exelixis (NASDAQ:EXEL) announced positive results in their phase 3 study for patients with Renal Cell Carcinoma — also known as kidney cancer. The phase 3 trial, known as the Meteor trial, recruited up to 658 patients with metastatic kidney… Continue Reading

0

Ohr Pharmaceuticals Obtains Positive Phase 2 Results For Retinal Vein Occlusion

(BiotechPickList) – Shares of Ohr Pharmaceuticals (NASDAQ:OHRP) closed the day up 67% after announcing positive phase 2 results for treatment of Retinal Vein Occlusion using a combination therapy. The phase 2 trial recruited 20 naive (not previously treated) patients with macular… Continue Reading

0

Johnson & Johnson Psoriasis Drug Makes It Out On Top In Phase 2b Trial

(BiotechPickList) –  Johnson & Johnson (NYSE:JNJ) announced today that it has successfully completed a phase IIb psoriasis study using its IL-23 drug blocker. The IL-23 blocker is also known as guselkumab and has done quite well to date for patients… Continue Reading

0

Arrowhead Doses First Patient For Rare Liver Disease

(BiotechPickList) – Arrowhead Research Corp (NASDAQ:ARWR) today announced that is has dosed the first patient in a phase 1 clinical trial for a rare liver disease. The drug being used in this phase 1 trial is known as ARC-AAT and… Continue Reading

0

Vanda Pharmaceuticals Announces Positive Results In Schizophrenia Patients Who Relapse

(BiotechPickList) – Today Vanda Pharmacduticals (NASDAQ:VNDA) announced positive results from a Relapse prevention study in patients with Schizophrenia. The trial is known as the REPRIEVE clinical study which was a randomized placebo control study. One thing to note was that… Continue Reading

0

Biomarin Posts Positive Phase 2 Results for Its Dwarfism Drug

(BiotechPickList) – Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) are up about 6% in after hours trade after the company reported positive phase 2 results in children with Achondroplasia — also known as the most common form of human dwarfism. The company’s… Continue Reading